Maria B. V. V.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 1 Evaluation of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase Mutations
- Evaluation of CC-95251 Monotherapy and in Combination with Antineoplastic Agents in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Pharmacokinetic, Safety, and Efficacy Evaluation of ASTX727 and Venetoclax in Adult Patients with Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 128 of 258 partner sites.
Specializations
Hematologic Disorders
This investigator specializes in treating Paroxysmal Nocturnal Hemoglobinuria (PNH), exploring innovative therapeutic approaches through complement inhibitor therapies.
- Complement inhibitor therapy evaluation
- Treatment-naïve PNH patient care
- Complement inhibitor switching strategies
The research interest extends to evaluating novel therapeutic options for patients both new to complement inhibitor therapy and those previously treated.
Acute Leukemia Research
Primary focus on developing treatments for various forms of acute myeloid leukemia (AML), including both newly diagnosed and relapsed/refractory cases.
- FLT3-ITD negative AML treatment
- Combination therapy approaches
- Novel therapeutic agents
The investigator explores innovative treatment combinations and targeted therapies for different AML patient populations.
Advanced Therapeutic Development
Expertise in evaluating novel compounds for hematologic malignancies, with particular attention to drug interactions and combination strategies.
- Pharmacokinetic studies
- Safety profile assessment
- Treatment optimization research
Research encompasses both early-phase and advanced clinical investigations of emerging therapeutic agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.